Acenocoumarol (Standard)

Acenocoumarol (Standard) is the analytical standard of Acenocoumarol. This product is intended for research and analytical applications. Acenocoumarol is an anticoagulant that functions as a Vitamin K antagonist. Acenocoumarol inhibits MAPK/ERK/JNK signaling pathway, reduces the nuclear translocation of NF-κB p65, activates Akt/GSK3β signaling pathway. Acenocoumarol induces apoptosis in cell A549, arrests cell cycle at S phase[1][2][3][4].

Product Specifications

CAS Number

[152-72-7]

UNSPSC

12352100

Target

Akt; Apoptosis; ERK; GSK-3; JNK; NF-κB; p38 MAPK; PKA; Reference Standards; VD/VDR

Related Pathways

Apoptosis; MAPK/ERK Pathway; NF-κB; Others; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Smiles

O=C1C(C(C2=CC=C([N+]([O-])=O)C=C2)CC(C)=O)=C(O)C3=CC=CC=C3O1

Molecular Formula

C19H15NO6

Molecular Weight

353.33

References & Citations

[1]Han HJ, et al., Acenocoumarol Exerts Anti-Inflammatory Activity via the Suppression of NF-κB and MAPK Pathways in RAW 264.7 Cells. Molecules. 2023 Feb 22;28 (5) :2075.|[2]Han H, et al., Acenocoumarol, an Anticoagulant Drug, Prevents Melanogenesis in B16F10 Melanoma Cells. Pharmaceuticals (Basel) . 2023 Apr 17;16 (4) :604.|[3]Warzecha Z, et al., Therapeutic Effect of Low Doses of Acenocoumarol in the Course of Ischemia/Reperfusion-Induced Acute Pancreatitis in Rats. Int. J. Mol. Sci.2017, 18, 882. Int J Mol Sci. 2019 Jun 24;20 (12) :3086.|[4]Maity S, et al. Exploring acenocoumarol and silodosin as allosteric EGFR inhibitors for the treatment of non-small cell lung cancer[J]. F1000Research, 2024, 13 (1398) : 1398.